Terms: = Gastric cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
269 results:
1. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy.
Zhao Y; Liu Z; Deng K; Qu H; Zhang Q; Zhou P; Yang M; Yang X; Wang H; Li R; Xia J
Int Immunopharmacol; 2024 May; 132():111998. PubMed ID: 38593510
[TBL] [Abstract] [Full Text] [Related]
2. HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.
Suo D; Gao X; Chen Q; Zeng T; Zhan J; Li G; Zheng Y; Zhu S; Yun J; Guan XY; Li Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):106. PubMed ID: 38589927
[TBL] [Abstract] [Full Text] [Related]
3. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
4. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
5. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract] [Full Text] [Related]
6. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
Pereira MA; Ramos MFKP; Cardili L; de Moraes RDR; Dias AR; Szor DJ; Zilberstein B; Alves VAF; de Mello ES; Ribeiro U
J Gastrointest Surg; 2024 Feb; 28(2):151-157. PubMed ID: 38445936
[TBL] [Abstract] [Full Text] [Related]
8. Identification of ferroptosis-related subtypes, characteristics of TME infiltration and development of prognostic models in gastric cancer.
Tang X; Yu Y; Liu N; Su Y; Zhang K; Zhai Z; Chen C; Sun W; Chen D; Ling R
Int Immunopharmacol; 2024 Mar; 130():111610. PubMed ID: 38402832
[TBL] [Abstract] [Full Text] [Related]
9. Treatment and prognostic implications of strong pd-l1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
10. Progress of PD-1/pd-l1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
11. Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma.
Zhang S; Liu S; Yue C; Liu Y; Zheng G; Zhang Y
Exp Cell Res; 2024 Mar; 436(1):113948. PubMed ID: 38307189
[TBL] [Abstract] [Full Text] [Related]
12. An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherapy outcomes.
Ying L; Hu Z; Lu Y; Tao Q; Xiong F; Shu Y; Yang Y; Qiao X; Peng C; Jiang Y; Han M; Xu M; Li X; Wang D
Oncoimmunology; 2024; 13(1):2303195. PubMed ID: 38235318
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Management of gastric cancer Treatment Regimens.
Boilève J; Touchefeu Y; Matysiak-Budnik T
Curr Top Microbiol Immunol; 2023; 444():279-304. PubMed ID: 38231223
[TBL] [Abstract] [Full Text] [Related]
14. Gut microbiome-derived butyrate inhibits the immunosuppressive factors pd-l1 and IL-10 in tumor-associated macrophages in gastric cancer.
Lee SY; Jhun J; Woo JS; Lee KH; Hwang SH; Moon J; Park G; Choi SS; Kim SJ; Jung YJ; Song KY; Cho ML
Gut Microbes; 2024; 16(1):2300846. PubMed ID: 38197259
[TBL] [Abstract] [Full Text] [Related]
15. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL; van de Haar J; van den Berg JG; van Sandick JW; Kodach LL; van Dieren JM; Balduzzi S; Grootscholten C; IJsselsteijn ME; Veenhof AAFA; Hartemink KJ; Vollebergh MA; Jurdi A; Sharma S; Spickard E; Owers EC; Bartels-Rutten A; den Hartog P; de Miranda NFCC; van Leerdam ME; Haanen JBAG; Schumacher TN; Voest EE; Chalabi M
Nat Med; 2024 Feb; 30(2):519-530. PubMed ID: 38191613
[TBL] [Abstract] [Full Text] [Related]
16. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
17. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.
Huang W; Xiong W; Tang L; Chen C; Yuan Q; Zhang C; Zhou K; Sun Z; Zhang T; Han Z; Feng H; Liang X; Zhong Y; Deng H; Yu L; Xu Y; Wang W; Shen L; Li G; Jiang Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38179695
[TBL] [Abstract] [Full Text] [Related]
18. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
[TBL] [Abstract] [Full Text] [Related]
19. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and pd-l1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
20. Expression and clinical significance of pd-l1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.
Quan Q; Guo L; Huang L; Liu Z; Guo T; Shen Y; Ding S; Liu C; Cao L
Medicine (Baltimore); 2023 Dec; 102(48):e36323. PubMed ID: 38050283
[TBL] [Abstract] [Full Text] [Related]
[Next]
